Get the Stockscreener App
1.56
0.00%
0.00
After Hours:
1.57
0.01
+0.64%
Pmv Pharmaceuticals Inc stock is traded at $1.56, with a volume of 170.96K.
It is up +0.00% in the last 24 hours and up +47.17% over the past month.
PMV Pharmaceuticals Inc is a precision oncology company. The company is engaged in the research and development of small molecule, tumor-agnostic therapies targeting p53 mutations, which can eliminate cancer cells. The key product candidate, rezatapopt, is designed to be an orally available small molecule that structurally corrects the mutant p53 protein with the Y220C mutation. Currently, the product candidates are undergoing preclinical and clinical testing, and company relies on third parties for the manufacture after marketing approvals.
See More
Previous Close:
$1.56
Open:
$1.57
24h Volume:
170.96K
Relative Volume:
0.32
Market Cap:
$83.01M
Revenue:
-
Net Income/Loss:
$-77.74M
P/E Ratio:
-1.0546
EPS:
-1.4793
Net Cash Flow:
$-73.61M
1W Performance:
-3.70%
1M Performance:
+47.17%
6M Performance:
+24.80%
1Y Performance:
+23.81%
1-Day Range:
$1.555
$1.599
1-Week Range:
$1.54
$1.64
52-Week Range:
$0.81
$1.88
Pmv Pharmaceuticals Inc Stock (PMVP) Company Profile
Name
Pmv Pharmaceuticals Inc
Sector
Industry
Phone
(609) 642-6670
Address
400 ALEXANDER PARK DRIVE, PRINCETON
Compare PMVP vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PMVP
Pmv Pharmaceuticals Inc
|
1.56 | 83.01M | 0 | -77.74M | -73.61M | -1.4793 |
|
VRTX
Vertex Pharmaceuticals Inc
|
462.49 | 118.41B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
759.05 | 80.02B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
706.03 | 43.52B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.42 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
287.33 | 32.13B | 5.36B | 287.73M | 924.18M | 2.5229 |
Pmv Pharmaceuticals Inc Stock (PMVP) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-08-24 | Upgrade | Oppenheimer | Perform → Outperform |
| May-13-24 | Initiated | Craig Hallum | Buy |
| Apr-12-24 | Initiated | Jefferies | Buy |
| Dec-27-23 | Initiated | Ladenburg Thalmann | Buy |
| Mar-02-22 | Upgrade | Oppenheimer | Perform → Outperform |
| Sep-22-21 | Upgrade | Goldman | Neutral → Buy |
| Aug-19-21 | Initiated | Oppenheimer | Perform |
| Aug-02-21 | Initiated | Guggenheim | Buy |
| Jul-29-21 | Initiated | H.C. Wainwright | Buy |
| Oct-20-20 | Initiated | BofA Securities | Buy |
| Oct-20-20 | Initiated | Cowen | Outperform |
| Oct-20-20 | Initiated | Evercore ISI | Outperform |
| Oct-20-20 | Initiated | Goldman | Neutral |
View All
Pmv Pharmaceuticals Inc Stock (PMVP) Latest News
US Market Wrap: Is PMV Pharmaceuticals Inc a potential multi bagger2026 Volatility Report & Growth Focused Stock Reports - baoquankhu1.vn
PMV Pharmaceuticals, Inc. (NASDAQ:PMVP) Short Interest Update - MarketBeat
PMV Pharmaceuticals Advances Rezatapopt Interaction Study, Signaling Steady Progress in TP53-Driven Oncology - TipRanks
PMV Pharmaceuticals (PMVP) CFO receives 240,000-share stock option grant - Stock Titan
COO at PMV Pharmaceuticals (NASDAQ: PMVP) awarded 319,270 options - Stock Titan
PMV Pharmaceuticals (NASDAQ:PMVP) Issues Quarterly Earnings Results, Beats Estimates By $0.06 EPS - MarketBeat
Trend Recap: Does TriNet Group Inc have pricing powerEarnings Overview Summary & Safe Capital Growth Stock Tips - baoquankhu1.vn
PMV Pharmaceuticals, Inc.Common Stock (NQ: PMVP - The Chronicle-Journal
Risk On: Whats the outlook for PMV Pharmaceuticals Incs sectorWeekly Trend Report & Free Technical Pattern Based Buy Signals - baoquankhu1.vn
PMV Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
PMVP Reports Positive Phase 2 Results, Eyes 2027 NDA Submission - GuruFocus
PMV Pharma (PMVP) Reports Decline in Cash Reserves by Year-End 2 - GuruFocus
PMV Pharmaceuticals Reports Progress in PYNNACLE Trial of Rezatapopt for Ovarian Cancer and Announces Orphan Drug Designation from FDA - Quiver Quantitative
PMV Pharmaceuticals 10-K: Revenue $0, EPS $(1.48) — FY2025 results - TradingView
PMVP: Net loss widened to $77.7M as rezatapopt advanced in trials; cash runway extends to Q2 2027 - TradingView
PMV Pharmaceuticals Reports Full Year 2025 Financial Results and Corporate Highlights - Yahoo Finance
PMVP Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
PMVP Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
PMV Pharmaceuticals Inc expected to post a loss of 40 cents a shareEarnings Preview - TradingView
Health Rounds: Researchers find cellular clues to explain faster pain recovery in men - marketscreener.com
PMV Pharma’s rezatapopt study published in New England Journal - Investing.com Australia
12 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga
PMV Pharmaceuticals (PMVP) Publishes Positive Phase 1 Results fo - GuruFocus
PMV Pharma’s rezatapopt study published in New England Journal By Investing.com - Investing.com UK
New England Journal of Medicine Publishes First-in-Human - GlobeNewswire
Risk Analysis: Is PMV Pharmaceuticals Inc benefiting from interest rate changes2025 Biggest Moves & Expert Approved Momentum Trade Ideas - baoquankhu1.vn
PMV Pharmaceuticals (PMVP) to Release Quarterly Earnings on Monday - Defense World
Avadel Pharmaceuticals (AVDL) to Release Earnings on Monday - Defense World
Decliners Report: Can NSYS lead its sector in growthTrade Exit Report & Accurate Technical Buy Alerts - baoquankhu1.vn
Signal Recap: How much upside does LNKB haveJuly 2025 PostEarnings & Verified Swing Trading Watchlists - baoquankhu1.vn
Dow Update: Is Oxbridge Re Holdings Limited benefiting from interest rate changes2025 Geopolitical Influence & Short-Term High Return Ideas - baoquankhu1.vn
Growth Review: Is Accretion Acquisition Corp Equity Right stock risky to hold nowMarket Activity Summary & Daily Chart Pattern Signal Reports - baoquankhu1.vn
Will PMV Pharmaceuticals Inc outperform its industry peersJuly 2025 WrapUp & Weekly Market Pulse Alerts - baoquankhu1.vn
PMV Pharmaceuticals (NASDAQ:PMVP) Trading Up 0.9%Time to Buy? - MarketBeat
Fund Flows: Whats the RSI of PMV Pharmaceuticals Inc stockMarket Sentiment Report & Fast Gaining Stock Reports - baoquankhu1.vn
Why Columbus Acquisition Corp stock is a value investor pickRate Cut & Weekly Watchlist of Top Performers - mfd.ru
Will NDLS stock deliver better than expected guidanceWeekly Trend Report & Weekly Stock Breakout Alerts - mfd.ru
PMVP PE Ratio & Valuation, Is PMVP Overvalued - Intellectia AI
Analysts Offer Insights on Healthcare Companies: Exelixis (EXEL) and OrganiGram Holdings (OGI) - The Globe and Mail
Guidance Update: Is PMV Pharmaceuticals Incs ROE strong enoughJuly 2025 PreEarnings & Weekly Stock Breakout Alerts - baoquankhu1.vn
Fed Watch: Will PMV Pharmaceuticals Inc outperform its industry peersAnalyst Upgrade & AI Powered Market Entry Strategies - baoquankhu1.vn
PMV Pharmaceuticals: Key Catalysts Approach in Q1 2026 - AD HOC NEWS
Tech Rally: Whats the RSI of PMV Pharmaceuticals Inc stockMarket Volume Summary & Technical Entry and Exit Tips - baoquankhu1.vn
Support Test: Whats the outlook for PMV Pharmaceuticals Incs sectorProduct Launch & Detailed Earnings Play Alerts - baoquankhu1.vn
Analysts Are Bullish on Top Healthcare Stocks: Palvella Therapeutics (PVLA), Xeris Pharmaceuticals (XERS) - The Globe and Mail
Caesarstone And 2 More Penny Stocks Worth Watching - simplywall.st
PMV Pharmaceuticals (NASDAQ:PMVP) Trading Up 3.4%Here's Why - MarketBeat
PMV Pharmaceuticals (NASDAQ:PMVP) Trading Up 3.4% – Here’s Why - Defense World
Will PMV Pharmaceuticals (NASDAQ:PMVP) Spend Its Cash Wisely? - simplywall.st
Weekly Earnings: Can MTRX generate free cash flowQuarterly Trade Summary & Safe Entry Zone Identification - baoquankhu1.vn
Stock Market Recap: Does LEGTWS have strong EBITDA marginsBear Alert & Low Risk Investment Opportunities - baoquankhu1.vn
Pmv Pharmaceuticals Inc Stock (PMVP) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.02%
0.46%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):